Review Article

Cytochrome P450 Metabolism of Betel Quid-Derived Compounds: Implications for the Development of Prevention Strategies for Oral and Pharyngeal Cancers

Che-Yi Lin, 1 Tien-Szu Pan, 2 Chun-Chan Ting, 3,4 Shih-Shin Liang, 5,6 Shu-Hung Huang, 7,8 Hsiu-Yueh Liu, 3,9 Edward Cheng-Chuan Ko, 3,10,11 Chung-Wei Wu, 10 Jen-Yang Tang, 12,13,14 and Ping-Ho Chen 3,14

1 Department of Oral and Maxillofacial Surgery, Chi Mei Hospital, Liouying 736, Taiwan
2 Department of Electronic Engineering, National Kaohsiung University of Applied Sciences, Kaohsiung 807, Taiwan
3 School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
4 Department of Periodontology, School of Dentistry, Aichi Gakuin University, Nagoya 464-8651, Japan
5 Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807, Taiwan
6 Center for Resources, Research and Development, Kaohsiung Medical University, Kaohsiung 807, Taiwan
7 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
8 Division of Plastic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan
9 Department of Dental Technology, Shu Zen College of Medicine and Management, Kaohsiung 807, Taiwan
10 Division of Oral and Maxillofacial Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
11 Departments of Cartilage and Bone Regeneration (Fujisoft), Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
12 Department of Radiation Oncology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
13 Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
14 Cancer Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

Correspondence should be addressed to Jen-Yang Tang; reyata@kmu.edu.tw and Ping-Ho Chen; phchenkmu@gmail.com

Received 22 April 2013; Accepted 20 May 2013


Copyright © 2013 Che-Yi Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Betel quid (BQ) products, with or without tobacco, have been classified by the International Agency for Research on Cancer (IARC) as group I human carcinogens that are associated with an elevated risk of oral potentially malignant disorders (OPMDs) and cancers of the oral cavity and pharynx. There are estimated 600 million BQ users worldwide. In Taiwan alone there are 2 million habitual users (approximately 10% of the population). Oral and pharyngeal cancers result from interactions between genes and environmental factors (BQ exposure). Cytochrome p450 (CYP) families are implicated in the metabolic activation of BQ- and areca nut-specific nitrosamines. In this review, we summarize the current knowledge base regarding CYP genetic variants and related oral disorders. In clinical applications, we focus on cancers of the oral cavity and pharynx and OPMDs associated with CYP gene polymorphisms, including CYP1A1, CYP2A6, CYP2E1, and CYP26B1. Our discussion of CYP polymorphisms provides insight into the importance of screening tests in OPMDs patients for the prevention of oral and pharyngeal cancers. Future studies will establish a strong foundation for the development of chemoprevention strategies, polymorphism-based clinical diagnostic tools (e.g., specific single-nucleotide polymorphism (SNP) “barcodes”), and effective treatments for BQ-related oral disorders.
1. Introduction

Oral and pharyngeal cancers are some of the most common cancers worldwide [1]. Taiwan is a hyperendemic area for oral and pharyngeal cancers [2]. In 2010, the age-standardized incidence rate adjusted by 2000 years world population (ASRW) of oral and pharyngeal cancers was 40.56 per 100 000 Taiwanese males and was ranked the fourth most prevalent cancer in Taiwan [3]. The ASRW of oral and pharyngeal cancers among Taiwanese males was also ranked one of the highest worldwide [2].

Oral submucous fibrosis (OSF), leukoplakia, erythroplakia, and lichen planus are a group of oral potentially malignant disorders (OPMDs) thought to be linked to the development of oral and pharyngeal cancers [4, 5]. Cases of oral and pharyngeal cancers are concentrated in Southeast Asia, where betel quid (BQ) chewing is prevalent [2]. Habitual BQ chewing is associated with an increased risk of oral and pharyngeal cancers and OPMDs [5–9]. Ko et al. demonstrated a significant association between BQ chewing without tobacco and the incidence of oral cancer [6]. In addition, BQ chewing is a major risk factor for OPMDs such as oral leukoplakia and OSF, and cigarette smoking was shown to have a modifying effect on chewing, based on an additive-interaction model in oral leukoplakia patients [7].

The fourth most frequently consumed psychoactive substance worldwide after caffeine, nicotine, and alcohol is BQ, a masticatory mixture that combines the areca nut (AN), betel leaf, slaked lime, and various local flavorings [10]. Approximately 10% of the global population (approximately 600 million users) chew some form of BQ, primarily in the Indo-Pakistan subcontinent, South and Southeast Asia, and the South Pacific islands, and a large number of South Asian immigrants to the United Kingdom, Africa, Australia, and the United States are also BQ chewers [10–12]. In Taiwan, chewing BQ is a popular habit, particularly among males, with approximately 2 million regular users [13]. In a previous study, we found that male Taiwanese oral and pharyngeal cancer patients with a history of high-frequency BQ use had poor survival [14, 15].

By 2004, the International Agency for Research on Cancer (IARC) declared that BQ without tobacco is carcinogenic to humans (group 1) and increases the risk of oral cancer [16]. Although the masticatory practices and ingredients in BQ differ in different regions of the world, the AN is a major component of BQ worldwide, and the IARC has reported that AN alone is a group 1 carcinogen in humans. In the presence of slaked lime, the most abundant alkaloid of AN, arecoline, is hydrolyzed to arecaidine during the chewing process [17]. Arecoline has been shown to be cytotoxic to mammalian cells in vivo and in vitro [18–20]. In vitro studies the mutagenicity and genotoxicity of arecoline and arecaidine have been examined primarily in short-term experiments [21]. However, in carcinogenicity studies in animals, the IARC (2004) reported that evidence indicating that arecoline may cause cancer is limited, but inadequate evidence for the carcinogenicity of arecaidine [16].

In general, exposure to AN-derived carcinogens, particularly the alkaloids and the AN-derived N-nitrosamines, increases the risk of OPMDs and cancers of the oral cavity and pharynx in BQ chewers. Cytochrome P450 (CYP) enzymes are monooxygenases that catalyze many reactions involving carcinogens [22, 23]. During phase I metabolism, CYP families play important roles in detoxifying AN-derived compounds, such as arecoline [24], and are involved in the metabolic activation of arecoline-related N-nitrosamines [25]. A previous study suggested that arecaidine and three N-oxide metabolites are generated by the CYP enzyme system [26].

Environmental carcinogens and genetic polymorphisms, either separately or jointly, play an important role in the occurrence of oral and pharyngeal cancers. Environmental factors, such as alcohol use, BQ chewing, and cigarette smoking, were significantly associated with the risk of oral and pharyngeal cancers and OPMDs, and a synergistic effect among the use of these substances was also observed [6, 7, 16]. The interactions of environmental and genetic factors in the tumorigenesis of oral and pharyngeal cancers have been shown to be affected by various CYP enzyme-mediated metabolic processes [27–30].

Several studies have indicated that CYP polymorphisms affect the metabolism of tobacco-derived carcinogens and the risk of oral cancer [31–33]. However, reports of the risk of oral and pharyngeal cancers and OPMDs associated with AN-derived carcinogens are scant. Our review focuses on the role of the CYP enzyme-mediated metabolism in OPMDs and oral and pharyngeal cancers among BQ users and evaluates emerging data that potentially implicate arecoline- and arecoline-derived N-nitrosamines in tumorigenesis. The effects of CYP polymorphisms are worthy of investigation to further understand the role of genetic factors in susceptibility to OPMDs and cancers of the oral cavity and pharynx and to aid the development of prevention strategies for cancers related to BQ use.

2. AN-Derived N-Nitrosamines

2.1. Carcinogenicity of N-Nitrosamines In Vitro. The chewing of AN is believed to produce carcinogenic N-nitrosamines. Arecoline is the major compound of AN. The N-nitrosation of arecoline has been shown to form N-nitrosoguvacoline (NGL), 3-methylnitrosaminopropionaldehyde (MNPA), and 3-methylnitrosaminopropionitrile (MNPN) in vitro [34]. Based on studies of Salmonella typhimurium YG7108, CYP2A6 was found to be the most efficient activator of MNPN, followed by CYP1A1, and NGL was activated by CYP2A6. The genotoxicity of NGL was observed to be substantially lower than that of MNPN or MNPA [35]. Thus, that the human CYP2A6 gene may play an important role in the mutagenic activation of AN-related N-nitrosamines has been suggested [35]. Studies on rodents have shown that MNPN, MNPA, and NGL are carcinogenic. In carcinogenicity studies on animals, the IARC (2004) determined that evidence of MNPN carcinogenicity is sufficient [16]. The carcinogenicity
of MNPN may be caused by DNA methylation, which has been observed in rats treated with MNPN [21,36].

2.2. Endogenous Nitrosation and N-Nitrosamines Carcinogenicity. Endogenous nitrosation occurs during BQ chewing, exposing BQ chewers to four N-nitrosamines derived from arecoline [37]. These AN (arecoline)-derived N-nitrosamines include MNPN, MNPA, NG, and N-nitrosoguvacine (NGC). These arecoline-derived N-nitrosamines are undetectable in the AN before chewing and are formed by the endogenous nitrosation of arecoline. Table 1 lists the maximum levels of NGL (142 ng/mL), NGC (26.6 ng/mL), and MNPN (11.4 ng/mL) in the saliva during BQ chewing without tobacco.

Many BQ chewers often swallow the quid juice, which contains the precursors of the nitrosamines. The pH of stomach acid likely facilitates the nitrosation of secondary and tertiary amines from the quid. A modified N-nitrosopropylene test showed that the urinary levels of N-nitrosopropylene, an endogenous nitrosation marker, are 2.4- to 6.5-fold higher in BQ chewers, with or without tobacco, compared to nonchewers [42,43]. Urinalysis of Syrian hamsters fed AN and an nitrite source detected NGL and its metabolite, N-nitrosopyrrolidone, indicating that exposure to nitrosamine carcinogens formed by endogenous nitrosation is likely higher among BQ chewers who swallow the BQ juice [46]. Several case-control studies have also indicated that swallowing the BQ juice is associated with a significant increase in the risk of oral cancer [6,47,48].

2.3. CYP1A1-Mediated Metabolism of N-Nitrosamines. In a study of *S. typhimurium* YG7108, CYP1A1 was the second most efficient activator of MNPN, after CYP2A6, and MNPA activation was catalyzed to a lesser extent by CYP1A1 [35]. Previous studies have demonstrated that CYP1A1 polymorphisms are associated with susceptibility to tobacco-related oral cancers [31-33,49,50]. Studies of the association between CYP1A1 polymorphisms and BQ-related oral cancers are scant.

Kao et al. found that people with the CYP1A1 Exon 7 polymorphism G/G genotype (val/val) are more susceptible to BQ-related oral cancer and OPMDs [29]. They found that people who have the G/G and A/G (ile/val) genotype have significantly higher rates ($P<0.0001$) of oral cancer (7.6% and 7.92%, resp.) and OPMDs (10% and 68.3%, resp.) than controls (1.4% and 53.4%, resp.). Kao et al. calculated odds ratios for the development of oral cancer of 18.86 and 5.08 for those with the G/G (95% CI, 3.61-98.52) or A/G (95% CI, 2.64-9.76) genotype of CYP1A1, respectively, and also reported odds ratios for the development of OPMDs of 15.23 and 2.67 for those with the G/G (95% CI, 2.76-83.98) or A/G (95% CI, 1.32-5.40) genotype, respectively. These novel findings indicated that people with the G (val) allele may have an earlier onset age of oral cancer [29]. Another study showed that people with the CYP1A1 m2 polymorphism within the *NcoI* restriction site (−/−) or the CYP1A1 m1 polymorphism at the *MspI* site (+/−) and (−/−) had a significantly higher risk of oral submucous fibrosis (OR = 8.25; 95% CI, 4.31-15.80; OR = 2.88; 95% CI, 1.57-5.24; and OR = 3.16; 95% CI, 1.10-9.04, resp.) [51].

2.4. The N-Nitrosamine-Metabolizing CYP2A6 Gene. Based on previous studies, we conclude that human CYP2A6 subfamily members play important roles in the metabolic activation of arecoline-related N-nitrosamines [52-54]. Located on human chromosome 19, the CYP2A6 gene consists of 350 kilobases located at 19q 12-19q 13.2 [55-57]. Thirteen alleles of the CYP2A6 gene have been identified (CYP2A6*1 through CYP2A6*11 and CYP2A6*1 × 2; Table 2). The CYP2A6*1 allele has 2 forms, CYP2A6*1A and CYP2A6*1B, that produce a gene conversion with the CYP2A7 gene in the 3′-untranslated region [58] and exhibit similar enzyme activity [58]. The CYP2A6*2, CYP2A6*3, CYP2A6*5, CYP2A6*6, CYP2A6*7, CYP2A6*8, CYP2A6*9, CYP2A6*10, and CYP2A6*11 genetic variants contain a different point mutation. In addition, the CYP2A6*10 variant contributes to variations in CYP2A6*7 and CYP2A6*8. The existence of CYP2A6*3 has been debated, but a previous study indicated that the CYP2A6*3 genetic variant was the result of multiple CYP2A6 and CYP2A7 gene conversions [59]. The CYP2A6*4 is from a deletion in the CYP2A6 gene. The CYP2A6*1 × 2 comprises a variation at 2 sites in the CYP2A6 gene, and the CYP2A6*1B allele is caused by gene conversion in the 3′-untranslated region of CYP2A7.

The various alleles of CYP2A6 express at least 13 different isoenzymes, among which CYP2A6 metabolically activates the *N*-alkyl nitrosamines, *N*-nitrosoronnicotinamide, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, which have relatively long alkyl chains [62,63]. Miyazaki et al. first reported that CYP2A6 subfamilies play important roles in the mutagenic activation of AN-derived N-nitrosamines [35]. The CYP2A6 P450 enzymes are the primary activators of MNPN. In Asia, the most common variant of CYP2A6 is CYP2A6*4 (the CYP2A6 deletion). The frequency of CYP2A6*4 is approximately 6.6% to 15.1% in the Chinese population. It is the most common genetic variant in the Japanese population, occurring at a frequency of 20.0% to 31.0% (Table 2).

People are classified as poor (PM), extensive (EM), or ultrarapid metabolizers (UM) based on their type of genetic variation [64]. The UM2 have 2 active alleles of the CYP2A6 gene, including the CYP2A6*1 × 2 variant. Phenotyping assays have indicated that 2 or more copies of active CYP2A6 alleles may result in a rapid nicotine metabolism. People with 1 or 2 copies of active gene alleles, such as CYP2A6*1/*1, are extensive metabolizers [60,65], whereas PMs are those with null alleles, such as CYP2A6*2/*2 or CYP2A6*4/*4, with no enzyme function or less activity regarding probe substrates. People who are homozygous for the CYP2A6*2 allele have little coumarin-hydroxylation activity (<0.1%) [60,61], and EMs exhibit low activity (<15%) when nicotine is used as the probe substrate [58,60,66,67].

Previous reports have indicated that the deletion of CYP2A6 (CYP2A6*4C) may reduce the risk of lung cancer [68-71], suggesting that people with CYP2A6*4C may not activate tobacco nitrosamines from smoking. Because a genetic variation within the CYP2A6 gene appears to reduce
xenobiotic activation, CYP2A6 polymorphisms may also reduce the metabolic activation of AN-derived nitrosamines.
In Sri Lanka, a study found that the deletion polymorphism, CYP2A6*4C/*4C, reduces susceptibility to oral squamous cell carcinoma (OR = 0.14; 95% CI, 0.03–0.72) among habitual BQ chewers with oral lesions, suggesting that BQ chewers with reduced CYP2A6 activity because of polymorphisms may be at lower risk for oral cancer [30].

2.5. The N-Nitrosamine-Metabolizing CYP2E Gene. The CYP2E family includes CYP2E1 and CYP2E2. The CYP2E1 gene has been shown to be the primary activator of N-nitrosodimethylamine and N-nitrosodiethylamine, which are N-nitrosamines with relatively short alkyl chains [62, 63]. A case-control study of 41 male oral cancer patients and 123 healthy controls found that people with the CYP2E1 cl/c2 or c2/c2 genotype had a higher risk of oral cancer (multicovariate-adjusted OR = 2.0; 95% CI, 0.8–5.4) than those with the cl/cl genotype [27]. However, the association was not statistically significant. Hung et al. also reported a significant association between CYP2E1 polymorphisms and oral cancer among those without BQ-chewing habits (OR = 4.7; 95% CI, 1.1–20.2), but not among BQ chewers [27]. All BQ chewers were also cigarette smokers, and the chewing habits had a significant effect on the risk of oral cancer. Thus, Hung et al. suggested that the risk of oral cancer associated with combined habits of BQ chewing and smoking may be too striking to have modified effects by the CYP2E1 genotype. A more recent study showed that polymorphisms in CYP2E1 within the PstI site (+/−) were significantly associated with oral submucous fibrosis (OR = 3.14; 95% CI, 1.14–8.62) [51].

2.6. Arecoline-Induced, CYP26B1-Mediated Retinoic Acid Metabolism. In a previous study, we treated normal human gingival fibroblasts (HGFs) with arecoline and screened for the presence of a novel CYP26B1 [81]. Klaassen et al. [81] found higher levels of RA-inducible CYP26 mRNA expression and higher RA turnover rates in oral squamous cell carcinoma cell lines, compared with noncancerous oral KB cells, and that oral KB cells from cancer patients exhibit a 15-fold higher RA turnover rate compared with noncancerous oral KB cells [83]. A previous study indicated that high-level CYP26 expression may be associated with head and neck cancer [82]. The expression of CYP26 was induced through an RA-receptor-mediated mechanism in breast and colon carcinoma cells [84]. A higher expression of CYP26 caused intracellular RA depletion in Barrett-associated adenocarcinoma [78], whereas other studies have indicated that the expression of CYP26 is downregulated in noncancerous human epidermis.

<table>
<thead>
<tr>
<th>BQ-specific N-nitrosamines</th>
<th>BQ alone (without tobacco)</th>
<th>BQ + tobacco</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>MNPN</td>
<td>0.5–11.4</td>
<td>0–71</td>
<td>Prokopczyk et al., 1987 [36]</td>
</tr>
<tr>
<td></td>
<td>0–5.9</td>
<td></td>
<td>Nair et al., 1985 [38]</td>
</tr>
<tr>
<td></td>
<td>0.6–8.8</td>
<td>3.1–23.5</td>
<td>Nair et al., 1987 [39]</td>
</tr>
<tr>
<td>NGL</td>
<td>2.2–9.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4.3–45&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Wenke et al., 1984 [40]</td>
</tr>
<tr>
<td></td>
<td>0–142</td>
<td></td>
<td>Stich, 1986 [41]</td>
</tr>
<tr>
<td>NGC</td>
<td>0–26.6</td>
<td>0–30.4</td>
<td>Nair et al., 1985 [38]</td>
</tr>
</tbody>
</table>

Adapted from [16].
BQ: betel quid.
<sup>a</sup>The data not reported.
<sup>b</sup>In ppb.

Table I: Detected saliva levels (ng/mL) of nitrosamines such as MNPN, NGL, and NGC in chewers with tobacco and without tobacco.
Table 2: The nomenclature of CYP2A6 and allele frequencies in population.

<table>
<thead>
<tr>
<th>Allele</th>
<th>Caucasian (%)</th>
<th>African American (%)</th>
<th>Frequencies in population</th>
<th>Nucleotide change</th>
<th>Effect</th>
<th>Enzyme activity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Swedes (%)</td>
<td>Finns (%)</td>
<td>Spaniards (%)</td>
<td>Chinese (%)</td>
</tr>
<tr>
<td>CYP2A6*1A</td>
<td>66.5</td>
<td>—</td>
<td>98.9</td>
<td>98.6</td>
<td>97.0</td>
<td>43.2</td>
</tr>
<tr>
<td>CYP2A6*1B</td>
<td>30.0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>40.6</td>
</tr>
<tr>
<td>CYP2A6*1 ∂</td>
<td>0.7</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.4</td>
</tr>
<tr>
<td>CYP2A6*2</td>
<td>1.1–3.0</td>
<td>0.3</td>
<td>1.1</td>
<td>1.4</td>
<td>3.0</td>
<td>0.0−0.7</td>
</tr>
<tr>
<td>CYP2A6*3</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>CYP2A6*4A</td>
<td>0.5–4.9</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>6.6–15.1</td>
</tr>
<tr>
<td>CYP2A6*4B</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>CYP2A6*4C</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>CYP2A6*4D</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>CYP2A6*5</td>
<td>0.0–0.2</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>1.0</td>
</tr>
<tr>
<td>CYP2A6*6</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.4</td>
</tr>
<tr>
<td>CYP2A6*7</td>
<td>1.0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>2.2</td>
</tr>
<tr>
<td>CYP2A6*8</td>
<td>0.0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>3.5</td>
</tr>
<tr>
<td>CYP2A6*9</td>
<td>5.2</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>15.7</td>
</tr>
<tr>
<td>CYP2A6*10</td>
<td>0.0</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>0.4</td>
</tr>
<tr>
<td>CYP2A6*11</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

Adapted from [57, 60, 61].

*aThe data not reported.
3. Discussion

Oral cancer is one of the most common cancers worldwide and was ranked the eighth leading cause of cancer-related deaths in 2000 [1]. Incidence rates of 8.8 and 5.1 per 100,000 cases and mortality rates of 7.3 and 3.2 per 100,000 cases have been reported for oral cancer among males and females, respectively [1]. In Taiwan, BQ production has increased approximately 44-fold [16]. An international study found that Taiwan had the fourth highest prevalence of oral and pharyngeal cancers, preceded by Papua New Guinea, the Solomon Islands, and Sri Lanka [2]. In BQ-endemic areas, oral and pharyngeal cancers and the most common OPMDs (such as OSF and oral leukoplakia) appear to be associated with BQ use, whereas cigarette smoking and heavy alcohol drinking are the major risk factors in western countries.

Numerous genes are involved in carcinogen metabolism, and most studies have found that CYP polymorphisms affect the risk of oral cancer associated with variations in the metabolism of tobacco-derived carcinogens. Arecoline, arecaidine, and other BQ-related metabolites may exist at nanogram concentrations in human blood, and the level of arecoline is significantly associated with the quantity of BQ used [87]. We summarized the findings of studies of the effects of CYP polymorphisms on BQ chewing-related symptoms, including cancer of the oral cavity and pharynx and OPMDs, in Table 3. Among xenobiotic metabolizing enzymes, CYPIA1, CYPA26, and CYPA25 may activate AN-derived nitrosamines. In addition, the expression of CYPA26 may be induced by arecoline and may be related to RA metabolism. The flowchart in Figure 1 depicts the main effects of CYP genetic variants on AN-induced carcinogenesis.

To the best of our knowledge, only 2 studies have reported a relationship between the genetic polymorphism of CYPIA1 and the risk of oral cancer and OPMDs [29, 51].
### Table 3: The association studies between cytochrome P450 (CYP) polymorphism and betel quid-related oral disorders.

<table>
<thead>
<tr>
<th>CYP gene</th>
<th>Cases/number</th>
<th>Chewing habit of cases/controls</th>
<th>OR (95% CI)</th>
<th>Conclusion</th>
<th>Population/reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>Oral cancer/106, Controls/146</td>
<td>BQ, 62.3%/15.0%</td>
<td>Gene effects: Exon 7 A/G (ile/val) A/G versus A/A, 5.08 (2.64–9.76)* G/G versus A/A, 18.86 (3.61–98.52)*</td>
<td>Subjects with CYP1A1 carrying G allele increased the risk for OPMDs and oral cancer</td>
<td>Taiwan/[29]</td>
</tr>
<tr>
<td></td>
<td>CYP1A1</td>
<td>OPMDs/60, Controls/146</td>
<td>BQ, 75.0%/15.0%</td>
<td>Gene effects: Exon 7 A/G (ile/val) A/G versus A/A, 2.67 (1.32–5.40)* G/G versus A/A, 15.23 (2.76–83.98)*</td>
<td>No significant association</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OSF/75, Controls/150</td>
<td>Gene effects: 3′UTR MspI site</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP2A6</td>
<td>Oral lesions/286 (15 oral cancer, 62 OSF and 209 leukoplakia), Controls/135</td>
<td>betel, 100%/100%</td>
<td>Gene effects &quot;1B&quot; 4C/ 4C versus &quot;1A&quot;/&quot;1A&quot;, 0.21 (0.05–0.88)* &quot;4C&quot;/4C versus &quot;1A&quot;/&quot;1A&quot;, 0.14 (0.03–0.72)*</td>
<td>Subjects with CYP2A6 deletion decreased the risk of oral cancer</td>
<td>Sri Lanka/[30]</td>
</tr>
<tr>
<td></td>
<td>Oral cancer/41, Controls/123</td>
<td>BQ, 73.2%/12.2%</td>
<td>Gene effects cl/c2 + c2/c2 versus cl/cl, 2.0 (0.8–5.4) Among nonchewers cl/c2 + c2/c2 versus cl/cl, 4.7 (1.1–20.2)* Among chewers cl/c2 + c2/c2 versus cl/cl, 0.8 (0.2–3.3)</td>
<td>A significant relationship between CYP2E1 polymorphisms and oral cancer risk was found among non-BQ chewers</td>
<td>Taiwan/[27]</td>
</tr>
<tr>
<td></td>
<td>Oral cancer/106, Controls/146</td>
<td>BQ, 85.4%/22.5%</td>
<td>Gene effects at PstI site (+/−) versus (+/+, 3.14 (1.14–8.62)*</td>
<td>Individuals with CYP2E1 at PstI site polymorphism (+/−) may confer a significantly increased risk for oral cancer</td>
<td>India/[51]</td>
</tr>
<tr>
<td>CYP26BI</td>
<td>Oral cancer/247, Controls/338</td>
<td>BQ, 85.4%/22.5%</td>
<td>Gene effects A versus C, 1.48 (1.16–1.87)* AA versus CC, 2.26 (1.35–3.80)* Gene-BQ (+/−) interplay AA-BQ (+) versus CC-BQ (−), 70.04 (13.62–360.11)*</td>
<td>BQ chewing interacted with CYP26BI-AA significantly increased the risk of oral cancer</td>
<td>Taiwan/[48]</td>
</tr>
</tbody>
</table>

OPMDs: oral potentially malignant disorders; OSF: oral submucous fibrosis; betel: betel quid chewing with or without tobacco; BQ: betel quid without tobacco; OR: odds ratios; CI: confidence interval; * statistical significance.

Higher-risk patients with the CYP1A1 G (val) allele should be strongly encouraged to avoid BQ use and maintain good oral hygiene. People with the CYP2A6* 4C/ 4C genetic variant may be at lower risk of oral cancer because their genotype suppresses the activation of AN-related procarcinogens [30]. The CYP2E1 polymorphisms may increase the risk of oral cancer [27, 51]. In addition, the findings of our previous study suggest that the combination of higher CYP26BI expression and polymorphism is associated with an increased risk of oral cancer [48].

Future studies on CYP26BI antagonists may identify novel RA-related methods of chemoprevention or treatment for OPMDs. Patients with high-risk alleles who chew BQ have an elevated risk for oral and pharyngeal cancers, and the risk is particularly high for OPMDs patients. We propose that the high-risk genotypes, such as CYP1A1, CYP2A6, CYP2E1, and CYP26BI, should be targeted for the development of a single-nucleotide polymorphism (SNP) gene chip for risk assessment in OPMDs patients, especially for those with BQ chewing habits.
4. Conclusion

The accumulation of such findings will be useful for the identification of high-risk patients and the development of novel therapeutic strategies for blocking the activation of AN-related compounds and targeting the CYP gene. Large-scale studies on the polymorphisms of CYP genes in BQ chewers and the genetic variants related to oral and pharyngeal cancers or OPMDs are warranted. The identification of molecular mechanisms elucidated by future pharmacogenomics studies will establish a strong foundation for the development of chemoprevention strategies, SNP-based clinical diagnostic tools (e.g., specific SNP barcodes for BQ-associated oral disorders), and effective treatments for BQ-related oral disorders.

Abbreviations

OPMDs: Oral potentially malignant disorders
BQ: Betel quid
AN: Areca nut
NGL: N-Nitrosoguavacoline
MNPA: 3-Methylnitrosaminopropionaldehyde
MNPN: 3-(Methylnitrosamino)propionitrile
NGC: N-Nitrosoguvacoline
RA: Retinoid acid

Conflict of Interests

The authors declare no conflict of interests.

Authors’ Contribution

Jen-Yang Tang and Ping-Ho Chen made equal contributions to this work.

Acknowledgments

This study was supported by Grants from the Chi-Mei Medical Center and Kaohsiung Medical University Research Foundation (100CM-KMU-13 and 101CM-KMU-12), a Grant from the Department of Health, Executive Yuan, Taiwan (DOH102-TD-C-III-002), and a Grant from National Science Council (NSC Grants 100-2113-M-037-012-MY2). The authors thank Dr. Ker-Kong Chen (School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Conservative Dentistry, Department of Dentistry, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan) for providing insightful comments on this paper.

References


J. A. White, H. Ramshaw, M. Taimi et al., “Identification of the human cytochrome P450, P450RAI-2, which is predominantly


[84] E. Sonneveld, C. E. van den Brink, B. M. van der Leede et al., "Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells," *Cell Growth and Differentiation*, vol. 9, no. 8, pp. 629–637, 1998.


